Johnson & Johnson (NYSE:JNJ) subsidiary Biosense Webster said today that it acquired Coherex Medical for an undisclosed amount.
Salt Lake City-based Coherex makes the Wavecrest anti-stroke device, which is designed to occlude the heart’s left atrial appendage to prevent blood clots from forming that could cause stroke.
“The addition of the Coherex WaveCrest system complements our comprehensive portfolio of therapeutic solutions for patients suffering from atrial fibrillation who not only suffer from reduced quality of life but also face a significantly greater risk of a stroke,” group chairman Shlomi Nachman said in prepared remarks. “As the exclusive distributor of this system in regions outside of the U.S. since 2013, we are confident it will be well-differentiated in the market.”
“The Coherex WaveCrest system offers substantial benefits for patients with atrial fibrillation who are at high risk for stroke, particularly for those who are contraindicated to anticoagulants and would therefore, be unprotected from the risk of cardio embolism,” added Coherex president & CEO Alex Martin. “We are excited that this technology will be coupled with Biosense Webster’s market leading therapies and look forward to bringing this innovative solution to more patients worldwide who stand to benefit from reduced risk of stroke.”
Diamond Bar, Calif.-based Biosense Webster said the WaveCrest device won CE Mark approval in the European Union in September 2013. The system is not approved for the U.S. market.
